Stemline Therapeutics, Inc. (STML) Posts Q1 Loss of 70c/Share

Stemline Therapeutics, Inc. (NASDAQ: STML) reported Q1 EPS of ($0.70), $0.02 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $71 thousand, versus $71 thousand reported last year.

For earnings history and earnings-related data on Stemline Therapeutics, Inc. (STML) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
• Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance